Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

RSS icon
Thumbnail

CMS extends bundled payments to 2025

Instead of concluding Dec. 31, 2023, the Bundled Payments for Care Improvement Advanced (BPCI Advanced) Model is scheduled to end Dec. 31, 2025.

Thumbnail

FDA launches new pilot program to improve medical device development

The U.S. Food and Drug Administration (FDA) has launched a new pilot program that aims to streamline medical device development, increase predictability and reduce the time from concept to commercialization.

Thumbnail

Most consumers are not shopping around for better healthcare prices

While the Biden administration and federal agencies have made price transparency a long-term goal for the U.S. healthcare industry, a recent study revealed Americans aren’t actually shopping around very often for better healthcare prices.

Example of the four types of breast tissue density. The density of fibroglandular tissue inside the breast impacts the ability to easily see cancers. Cancers are very easy to spot in fatty breasts, but are almost impossible to find in extremely dense breasts. These examples show craniocaudal mammogram findings characterized as almost entirely fatty (far left), scattered areas of fibroglandular density (second from left), heterogeneously dense (second from right), and extremely dense (far right). RSNA

Breast density notification laws blanket 90% of U.S. women, yet still no national reporting standard is at hand. Why is that?

Dense breast experts Wendie Berg, MD, and JoAnn Pushkin, executive director of DenseBreast-info Inc., explain the current status of breast density patient inform laws, reimbursement and new technologies to aid cancer detection. 

files paperwork work load

CMS aims to create centralized directory

According to the agency, directories can serve as important resources for patients who need to locate providers or compare health plan networks.

Dhanunjaya "DJ" Lakkireddy, MD, executive medical director for the Kansas City Heart Rhythm Institute at HCA Midwest Health, professor of medicine at the University of Missouri, Columbia, deputy editor for the the Journal of Atrial Fibrillation, and serves on the HRS Board of Trustees and section steering committee chair for the ACC, explains the potentially devastating impact of Medicare cuts on electrophysiology (EP) and patient care.

VIDEO: Medicare cuts could devastate the field of electrophysiology

"By imposing a 35%-42% cut, [CMS] has essentially created a scenario where it is going to destroy electrophysiology as a field," explained Dhanunjaya "DJ" Lakkireddy, MD.

Industry insights: 4 healthcare executives discuss the biggest challenges in cardiology today

We spoke to executives from some of healthcare's most prominent vendors to find out what challenges are on their radar in 2022 and beyond. 

Thumbnail

Healthcare groups ask DOJ for protection against violence over gender-affirming care

Three major healthcare groups are taking a stand against threats of violence over gender-affirming care by asking the Department of Justice to get involved. 

 

Displaying 489 - 496 of 2733

Around the web

Cardiovascular Business
Cardiology groups cheer new bill that would improve access to Medicare claims data

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Cardiovascular Business
Watchdog group, fearful of fraud, wants more oversight for remote patient monitoring

Cardiologists and other physicians may soon need to provide much more information when ordering remote patient monitoring for Medicare patients.

Cardiovascular Business
Most recalled cardiovascular devices gained FDA approval with little to no clinical evidence

Why are so many cardiovascular devices involved in Class I recalls? One possible reason could be the large number of devices hitting the market without undergoing much premarket clinical testing. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup